Who We Are & What We Do
AI will transform industries and markets everywhere. Unique insight gleaned from ancient wisdom and new innovation is possible with AI. The challenge is how to bridge old ways of thinking to usher in a new era of prosperity for everyone. Getting smarter about what we do each day is vital to our future. To improve how we live and work, we must make breakthrough discoveries to extend prosperity, health and well-being for everyone on the planet.
Our mission is to enhance global development by integrating ancient wisdom and modern-day discovery to inform people on how to improve the way they live and work. We use advanced AI models to produce data that organizations need to improve operational performance. This involves the delivery of vital insight workers everywhere can use to improve the health, well-being and happiness of family, friends and colleagues. Opportunity to produce and deliver game-changing insight makes it possible for more and more people to learn how to improve overall quality of life and greater value and prosperity.
While AI has existed for decades, the introduction of ChatGPT, Grok and other AI tools has changed everything. The challenge is that most corporations are not ready for AI. Poor data quality is a huge problem. Unstructured, biased and incomplete data must get cleaned up to become useful. Corporations need core data models that they can use to train AI algorithms to optimize operational performance. These models are based on a data structure this is unique to every business. CorporateDNA represents baseline data that organizations need to streamline operations, improve worker productivity and optimize the health and well-being of employees while also helping to reduce costs. We developed corporateDNA from historic economic, geographic, worker and activity-based data.
Global Investment & GEM Analytics LLC
Founded in 1989, Global Investments pioneered the worldwide Digital Asset Management (DAM) market over 25 years to amass data on the global market based on information production. Over $20M was initially invested to build industry, market, country, corporate and solution provider profiles, technology calculators, knowledge worker activity models, and best practices data needed to assess productivity when new capabilities like AI get deployed. To support the need to advance corporate decision making, GEM Analytics was formed to develop an advanced platform to measure, track and assess global commerce across all known industries and markets. Over the past 20 years, our GeoEconoMetric (GEM) AI Platform was developed from proprietary source data to measure and evaluate value creation based on microlevels of global performance metrics and productivity data. Opportunity to apply these capabilities across all industry segments is enormous - especially to transform the global healthcare market.
One area of opportunity is to diagnose disease progression and to assess and quantify global market potential for new epigenetic and nutraceutical cures that can combat diseases such as Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Opportunity to deliver breakthrough insight to improve health and wellness practices is now possible. Integration of GEM's cDNA & GeoEconoMetric data models with trillions of raw healthcare metrics from TALON Health Tech creates opportunity to develop new forms of insight that have never been seen before. Imagine having the insight to help individuals throughout the world to navigate healthcare by delivering treatment and service insight to personalize care based on individual needs. It is now possible to access and integrate ancient healthcare wisdom with modern knowledge to create personalized information and data that individuals need to serve healthcare needs. Our mission is to provide the strategic information services needed to support epigenetic and nutraceutical innovation with AI to support worldwide healthcare market development.
TALON Health Tech (MMS Analytics)
Enactment of the Health Care Price Transparency Act of 2023 created opportunity to improve patient healthcare. The act enables individuals to get more engaged in their own healthcare, plus creates incentives to save on healthcare costs. The Act mandates that all US health insurance carriers (Anthem, UnitedHealthcare, Cigna, Aetna, Kaiser Permanente, etc.), hospitals (Massachusetts General, Johns Hopkins, Cleveland Clinic, Brigham and Women’s, MD Anderson, etc.), ambulatory surgical centers, imaging services, and clinical laboratories must make personalized healthcare pricing information available to plan enrollees and patients in machine-readable files (MRFs). These files are generated by extracting data from billions of patient records that contain vital information that can be processed with AI to identify breakthrough information. Our opportunity is to assess, value and compare how outdated practices and procedures can be improved by tracking and monitoring disease progression and patient costs (doctors’ visits to open heart surgery). The challenge with Health Care Price Transparency Act of 2023 is that there are billions of records that must be turned into MRFs by old companies with outdated technology. The ability to collect and ingest trillions of raw data elements related to healthcare is extremely complex due to the number of sources where the data is produced, plus the sheer scale of the work. Opportunity to ingest this data into a comprehensive system is substantial. AI creates opportunity to process this data to create a huge source of patient data to improve healthcare, first in the US and then globally.
Founded in 2014, TALON Health Tech (MMS Analytics) in Portsmouth, NH has invested over $30M over 10 years collecting and ingest MRFs managed by advanced AI platform to service patients, insurance carriers, third party administrators, healthcare providers and US practitioners. Development of the most comprehensive sources of patient records and procedure data in the US has created opportunity to process trillions of raw data elements related to healthcare more than any other source in the world.
American Medical Holdings, Inc. & Badmaev Natural Drug Foundation
Dr. Vladimir Badmaev founded American Medical Holdings, Inc. and Badmaev Natural Drug Foundation to integrate traditional Oriental and Western medicine concepts that span back generations. The westward odyssey began in 1851 when Dr. Alexander Badmaev (Sul-Tim Badma) was invited from Buryatia (Lake Baikal) to St. Petersburg, Russia (west’s first Tibetan Pharmacy). His brother, Peter, became personal physician to the Russian Czar, Nicholas II. Following the Bolshevik Revolution of 1917, Dr. Vladimir Badmaev Sr. moved to Poland (Warsaw’s Tibetan Pharmacy 1932). In the 1960s, Dr. Peter Badmaev Jr. established Tibetan medicine in Switzerland and in Western Europe. In 1984, Dr. Vladimir Badmaev Jr. established the Badmaev Natural Drug Foundation (USA) and in 2009 American Medical Holdings Inc.
There are new ways to cultivate, process and extract molecules and nutrients and food from plants, animals and minerals. There are organic ways to cultivate and manufacture nutrients without the use of harmful chemicals to reduce environmental impact for farmers and newly developed products. The point is not to taint products with solvents used to extract molecules and compounds from plants, animals, and minerals by using new extraction technologies to avoid putting waste chemicals into fields and rivers. Our focus has been on the integration of the traditional medical systems like Ayurveda, Tibetan and Chinese traditions into contemporary medical practice. We specialize in using knowledge of botanical formulas with science-derived pharmacology with botanical treatments to create enriched generations-old healthcare wisdom to create modern day formulations and treatments.
RNT Holdings, Inc.
The epigenetic compound product, 6-Shogaol / IP, from RNT and their other natural molecules offer such strategic capabilities to these global markets. RNT Holdings, Inc. Nutra and Pharma Strategic Program and development of 6-Shogaol Product IP creates opportunity to address the worldwide epigenetics market for MDS and AML. 6-Shogaols is the first in a series of compounds that are ready for commercial development and distribution. Other products of interest include: Greenselenium® (Bioavailable selenium) a dietary supplement in the US market to address chronic inflammation. SlimTrym® (poly methoxy-flavones, green tea catechins, and lychee fruit) is a dietary supplement developed for the prevention and treatment of obesity. Turmericimmune™ (water extract of Curcuma longa (L.) [vern. Turmeric] roots) is a dietary supplement developed to support tissue repair, regeneration and immunity. FB3® Fusion (Coleus forskohlii (Briq.), Salacia reticulata (Wight.), Sesamum indicum (L.) represents a dietary supplement used to support health weight management. Kannan™ (Sceletium tortuosum) is a dietary supplement developed to address stress, mood, anxiety, cognition, depression and stamina. Adaptrin® is a dietary supplement that supports development of healthy cardiovascular and immune systems. Based on the long-standing tradition of nutritional use and published studies, Adaptrin lowers stress levels, sharpens memory, overall energy and alertness, sleep patterns; and promotes an increased general subjective sense of well-being. Serenity-151™ (contains Adaptogens) is a dietary supplement that addresses anti-stress and anti-sleep disorders, improve blood microcirculation, tissue oxygenation, and nourishment while improving intellectual performance, emotional composure, and memory function. Vigor-149 a dietary supplement used to maintain hormonal balance and libido in andropause, or menopause, etc.